Rivaroxaban
All-cause Mortality
Canadian Network for Observational Drug Effect Studies, CNODESSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the All-cause Mortality cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
WARFARIN Canadian Network for Observational Drug Effect Studies, CNODES | D |
Same molecule, other indications
Rivaroxaban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →